The efficacy and safety of induction therapy with autogenous mesenchymal stem cells perfusion before operation in cadaveric kidney transplantation
10.3760/cma.j.issn.0254-1785.2011.11.002
- VernacularTitle:术前自体骨髓间充质干细胞输注用于肾移植诱导治疗的临床研究
- Author:
Weizhen WU
;
Jianming TAN
;
Xinghui SUN
;
Jin CHEN
;
Shunliang YANG
;
Jinquan CAI
;
Junqi GUO
;
Qinghua WANG
;
Fang LUO
- Publication Type:Journal Article
- Keywords:
Kidney transplantation;
Mesenchymal stem cell;
Precaution;
Graft rejection
- From:
Chinese Journal of Organ Transplantation
2011;32(11):647-650
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of mesenchymal stem cells(MSCs)in preventing early acute rejection after renal transplantation.Methods Eighty-eight primary cadaveric renal allograft recipients in our department were randomized into two groups treated with bone marrow MSCs (BMSCs group,n =43) or not (control group,n =45).Main immunosuppressive therapy regimen consisted of steroids,tacrolimus or cyclosporine and mycophenolate mofetil in all recipients.Estimated glomerular filtration rate (eGFR) of transplant kidney,incidence of acute reaction (AR),graft survival and incidence of adverse events were recorded within 24 months.Results In BMSCs group,the incidence of AR was 4.7 ％ and 9.3 ％ at 3rd month and 6th month respectively,significantly lower than 20.0 ％ and 26.7 ％ (P＜0.05) in the control group.The eGFR at day 7,14and 30 post-transplantation was significantly higher in the BMSCs group than in the control group (P＜0.01,P＜0.01,P＜0.05 respectively).The incidence of adverse events in the BMSCs group and the control group was 44.2 ％ (19/43) and 66.7 ％ (30/45,P ＜ 0.05) respectively and the rate of infection was 37.2 ％ (16/43) and 33.3 ％ ( 15/46,P ＞ 0.05) respectively within 24 months.Conclusion Induction therapy with autogenous BMSCs appeared to be more effective in the prevention of AR following cadaveric kidney transplantation and was associated with better clinical outcomes as far as early renal graft function without compromising patient safety.
